Product Description
18F-BMS-986327, a novel positron-emitting LPAR1 binding tracer,
Mechanisms of Action: Imaging Agent
Novel Mechanism: No
Modality: Diagnostic Agent
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Bristol-Myers Squibb
Company Location: Eastern America
Company Founding Year: 1989
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Cardiomyopathy, Hypertrophic
Phase 1: Idiopathic Pulmonary Fibrosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05174416 |
LB2001-301 | P3 |
Completed |
Cardiomyopathy, Hypertrophic |
2023-03-06 |
2024-09-20 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT04069143 |
IM033-002 | P1 |
Completed |
Idiopathic Pulmonary Fibrosis |
2022-07-12 |
2023-03-08 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date |
Recent News Events
Date |
Type |
Title |
|---|